Cargando…

An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy

PURPOSE: To analyze clinical toxicity and quality-of-life (QOL) outcomes among patients with stage I non-small cell lung cancer (NSCLC) after stereotactic body radiation therapy (SBRT) as a function of radiation dose and volume parameters. METHODS AND MATERIALS: In this institutional review board–ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Devpura, Suneetha, Feldman, Aharon M., Rusu, Samuel D., Mayyas, Essa, Movsas, Avielle, Brown, Stephen L., Cook, Andrew, Simoff, Michael J., Sun, Zhen, Lu, Mei, Vance, Sean, Ajlouni, Munther I., Siddiqui, M. Salim, Chetty, Indrin J., Movsas, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655385/
https://www.ncbi.nlm.nih.gov/pubmed/34934866
http://dx.doi.org/10.1016/j.adro.2021.100815
_version_ 1784612061654810624
author Devpura, Suneetha
Feldman, Aharon M.
Rusu, Samuel D.
Mayyas, Essa
Movsas, Avielle
Brown, Stephen L.
Cook, Andrew
Simoff, Michael J.
Sun, Zhen
Lu, Mei
Vance, Sean
Ajlouni, Munther I.
Siddiqui, M. Salim
Chetty, Indrin J.
Movsas, Benjamin
author_facet Devpura, Suneetha
Feldman, Aharon M.
Rusu, Samuel D.
Mayyas, Essa
Movsas, Avielle
Brown, Stephen L.
Cook, Andrew
Simoff, Michael J.
Sun, Zhen
Lu, Mei
Vance, Sean
Ajlouni, Munther I.
Siddiqui, M. Salim
Chetty, Indrin J.
Movsas, Benjamin
author_sort Devpura, Suneetha
collection PubMed
description PURPOSE: To analyze clinical toxicity and quality-of-life (QOL) outcomes among patients with stage I non-small cell lung cancer (NSCLC) after stereotactic body radiation therapy (SBRT) as a function of radiation dose and volume parameters. METHODS AND MATERIALS: In this institutional review board–approved study, 55 patients with stage I NSCLC who received SBRT (12 Gy × 4) and completed QOL forms were analyzed. Clinical symptoms and QOL outcomes were measured at baseline and at 3, 6, 12, 18, 24, and 36 months after SBRT. Clinical toxicity was graded using the Common Terminology Criteria for Adverse Events, version 4.0. Quality of life was followed using the validated Functional Assessment of Cancer Therapy-Lung-Trial Outcome Index (FACT-L-TOI) instrument. Dosimetric parameters including the mean lung radiation dose and the volume of normal lung receiving greater than 5, 10, 13, or 20 Gy (V(5), V(10), V(13), and V(20)) were measured from the radiation treatment plan. Student t tests and Pearson correlation analyses were used to examine the relationships between radiation lung metrics and clinically meaningful changes in QOL and/or clinical toxic effects. The Kaplan-Meier method was used to estimate rates of local control (LC), disease-free survival (DFS), and overall survival (OS). RESULTS: With a median follow-up of 24 months, the 3-year LC, DFS, and OS were 93%, 65%, and 84%, respectively, with a 5.5% rate of grade-3 toxic effects and no grade 4 or 5 toxic effects. Clinically meaningful declines in patient-reported QOL (FACT-L-TOI, lung cancer subscale, physical well-being, and/or functional well-being) posttreatment significantly correlated with increased dosimetric parameters such as V(10), V(13), and V(20). CONCLUSION: Although lung SBRT was associated with excellent LC and minimal clinical toxic effects for early-stage NSCLC, clinically meaningful declines in QOL were significantly correlated with increasing lung dose and volume parameters.
format Online
Article
Text
id pubmed-8655385
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86553852021-12-20 An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy Devpura, Suneetha Feldman, Aharon M. Rusu, Samuel D. Mayyas, Essa Movsas, Avielle Brown, Stephen L. Cook, Andrew Simoff, Michael J. Sun, Zhen Lu, Mei Vance, Sean Ajlouni, Munther I. Siddiqui, M. Salim Chetty, Indrin J. Movsas, Benjamin Adv Radiat Oncol Scientific Article PURPOSE: To analyze clinical toxicity and quality-of-life (QOL) outcomes among patients with stage I non-small cell lung cancer (NSCLC) after stereotactic body radiation therapy (SBRT) as a function of radiation dose and volume parameters. METHODS AND MATERIALS: In this institutional review board–approved study, 55 patients with stage I NSCLC who received SBRT (12 Gy × 4) and completed QOL forms were analyzed. Clinical symptoms and QOL outcomes were measured at baseline and at 3, 6, 12, 18, 24, and 36 months after SBRT. Clinical toxicity was graded using the Common Terminology Criteria for Adverse Events, version 4.0. Quality of life was followed using the validated Functional Assessment of Cancer Therapy-Lung-Trial Outcome Index (FACT-L-TOI) instrument. Dosimetric parameters including the mean lung radiation dose and the volume of normal lung receiving greater than 5, 10, 13, or 20 Gy (V(5), V(10), V(13), and V(20)) were measured from the radiation treatment plan. Student t tests and Pearson correlation analyses were used to examine the relationships between radiation lung metrics and clinically meaningful changes in QOL and/or clinical toxic effects. The Kaplan-Meier method was used to estimate rates of local control (LC), disease-free survival (DFS), and overall survival (OS). RESULTS: With a median follow-up of 24 months, the 3-year LC, DFS, and OS were 93%, 65%, and 84%, respectively, with a 5.5% rate of grade-3 toxic effects and no grade 4 or 5 toxic effects. Clinically meaningful declines in patient-reported QOL (FACT-L-TOI, lung cancer subscale, physical well-being, and/or functional well-being) posttreatment significantly correlated with increased dosimetric parameters such as V(10), V(13), and V(20). CONCLUSION: Although lung SBRT was associated with excellent LC and minimal clinical toxic effects for early-stage NSCLC, clinically meaningful declines in QOL were significantly correlated with increasing lung dose and volume parameters. Elsevier 2021-09-29 /pmc/articles/PMC8655385/ /pubmed/34934866 http://dx.doi.org/10.1016/j.adro.2021.100815 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Devpura, Suneetha
Feldman, Aharon M.
Rusu, Samuel D.
Mayyas, Essa
Movsas, Avielle
Brown, Stephen L.
Cook, Andrew
Simoff, Michael J.
Sun, Zhen
Lu, Mei
Vance, Sean
Ajlouni, Munther I.
Siddiqui, M. Salim
Chetty, Indrin J.
Movsas, Benjamin
An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy
title An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy
title_full An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy
title_fullStr An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy
title_full_unstemmed An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy
title_short An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy
title_sort analysis of clinical toxic effects and quality of life as a function of radiation dose and volume after lung stereotactic body radiation therapy
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655385/
https://www.ncbi.nlm.nih.gov/pubmed/34934866
http://dx.doi.org/10.1016/j.adro.2021.100815
work_keys_str_mv AT devpurasuneetha ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT feldmanaharonm ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT rususamueld ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT mayyasessa ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT movsasavielle ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT brownstephenl ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT cookandrew ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT simoffmichaelj ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT sunzhen ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT lumei ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT vancesean ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT ajlounimuntheri ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT siddiquimsalim ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT chettyindrinj ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT movsasbenjamin ananalysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT devpurasuneetha analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT feldmanaharonm analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT rususamueld analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT mayyasessa analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT movsasavielle analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT brownstephenl analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT cookandrew analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT simoffmichaelj analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT sunzhen analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT lumei analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT vancesean analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT ajlounimuntheri analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT siddiquimsalim analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT chettyindrinj analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy
AT movsasbenjamin analysisofclinicaltoxiceffectsandqualityoflifeasafunctionofradiationdoseandvolumeafterlungstereotacticbodyradiationtherapy